|
Delayed
OTC Markets
17:30:56 21/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 15.06 USD | +0.67% |
|
+2.31% | +13.32% |
| 08-17 | CLSA Starts Astellas Pharma at Accumulate with 3,000 Yen Price Target | MT |
| 08-10 | AbCellera's menopause drug cuts hot flashes in mid-stage trial, shares surge | RE |
Company Valuation: Astellas Pharma Inc.
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 3,519,738 | 3,381,409 | 2,946,773 | 2,589,390 | 4,512,563 | 4,279,924 | - | - |
| Change | - | -3.93% | -12.85% | -12.13% | 74.27% | -5.16% | - | - |
| Enterprise Value (EV) 1 | 3,203,752 | 3,004,569 | 2,611,086 | 3,232,444 | 4,796,910 | 4,238,050 | 3,840,850 | 3,482,571 |
| Change | - | -6.22% | -13.1% | 23.8% | 48.4% | -11.65% | -9.37% | -9.33% |
| P/E | 28.5x | 34.7x | 173x | 51x | 15.5x | 11.6x | 12.3x | 15.8x |
| PBR | 2.39x | 2.24x | 1.85x | 1.71x | 2.47x | 2.11x | 1.94x | 1.85x |
| PEG | - | -1.8x | -2.1x | 0x | 0x | 0.4x | -2.13x | -0.7x |
| Capitalization / Revenue | 2.72x | 2.23x | 1.84x | 1.35x | 2.11x | 1.85x | 2x | 2.26x |
| EV / Revenue | 2.47x | 1.98x | 1.63x | 1.69x | 2.24x | 1.83x | 1.8x | 1.84x |
| EV / EBITDA | 13.6x | 12.6x | 14.2x | 13.5x | 8.31x | 5.92x | 5.8x | 6.24x |
| EV / EBIT | 20.6x | 22.6x | 102x | 78.8x | 12.5x | 8.75x | 8.5x | 9.47x |
| EV / FCF | 14.1x | 10.3x | -3.88x | 20.5x | 9.72x | 9.71x | 7.45x | 7.46x |
| FCF Yield | 7.08% | 9.7% | -25.8% | 4.87% | 10.3% | 10.3% | 13.4% | 13.4% |
| Dividend per Share 2 | 50 | 60 | 70 | 74 | 78 | 80.29 | 82.86 | 85.15 |
| Rate of return | 2.62% | 3.19% | 4.26% | 5.12% | 3.1% | 3.36% | 3.47% | 3.57% |
| EPS 2 | 67.08 | 54.24 | 9.51 | 28.35 | 162.8 | 205.9 | 194 | 150.9 |
| Distribution rate | 74.5% | 111% | 736% | 261% | 47.9% | 39% | 42.7% | 56.4% |
| Net sales 1 | 1,296,163 | 1,518,619 | 1,603,672 | 1,912,323 | 2,139,245 | 2,315,496 | 2,136,534 | 1,896,709 |
| EBITDA 1 | 235,370 | 238,767 | 183,358 | 240,171 | 577,227 | 716,076 | 662,456 | 558,086 |
| EBIT 1 | 155,686 | 133,029 | 25,518 | 41,039 | 382,633 | 484,244 | 452,097 | 367,633 |
| Net income 1 | 124,086 | 98,714 | 17,045 | 50,747 | 291,535 | 355,833 | 332,560 | 252,140 |
| Net Debt 1 | -315,986 | -376,840 | -335,687 | 643,054 | 284,347 | -41,873 | -439,074 | -797,352 |
| Reference price 2 | 1,911.00 | 1,883.00 | 1,643.50 | 1,446.50 | 2,519.00 | 2,387.00 | 2,387.00 | 2,387.00 |
| Nbr of stocks (in thousands) | 1,841,831 | 1,795,756 | 1,792,986 | 1,790,107 | 1,791,411 | 1,793,014 | - | - |
| Announcement Date | 27/04/22 | 27/04/23 | 25/04/24 | 25/04/25 | 27/04/26 | - | - | - |
1JPY in Million2JPY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 35.55x | 12.84x | 26.06x | 0.55% | 1,109B | |
| 29.74x | - | - | 2.01% | 644B | |
| 33.42x | 7.74x | 16.11x | 2.62% | 463B | |
| 20.72x | 4.91x | 12.16x | 2.69% | 371B | |
| 22.47x | 5.78x | 14.33x | 2.76% | 301B | |
| 21.12x | 4.35x | 12.35x | 2.02% | 256B | |
| 27.43x | 7.09x | 12.59x | 2.33% | 234B | |
| 13.47x | 4.79x | 10.05x | 3.81% | 205B | |
| -43.83x | 6.34x | 24.76x | 2.3% | 178B | |
| Average | 17.79x | 6.73x | 16.05x | 2.34% | 417.9B | |
| Weighted average by Cap. | 25.34x | 8.43x | 18.53x | 1.91% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 4503 Stock
- ALPMY Stock
- Valuation Astellas Pharma Inc.
Select your edition
All financial news and data tailored to specific country editions
